Haemophilia occurs in every part of the world. The World Federation of Hemophilia (WFH) has highlighted that, globally, only 25% of people affected receive access to treatment. Sobi and Biogen want to be part of changing this.

Clotting factors are a part of proper treatment and care for people with haemophilia. Between 1996 and 2012, the World Federation of Hemophilia (WFH) has distributed 245 million International Units of donated clotting factor therapy to the developing world – an average of 15 million IUs per year. With this donation, Sobi and Biogen will be making on average an additional 100 million IUs available per year to people with haemophilia who are currently not receiving adequate treatment. Sobi and Biogen Idec have the possibility to make treatment available at this scale, thanks to our large-scale manufacturing technology.

The first 500 million IUs have already been earmarked for the World Federation of Hemophilia (WFH) to use in its “Close the Gap” programme. Our aim is for WFH to be able to significantly advance their ambition to “Close the Gap”, allowing people with haemophilia to stand a real chance of receiving access to treatment, no matter where they live. Our commitment to support access to treatment stems from our belief that securing access to safe, effective and reliable treatment is a shared societal responsibility. By working with the WFH and their long-established programme to “Close the Gap”, we hope that our experience can give a chance of effective treatment for people with haemophilia across the globe. We are also supporting the transportation and supply of factor by the WFH to allow people to have access to the treatment where they need it, when they need it.

By making the commitment to donate 1 billion IUs, spanning the next 10 years, Sobi and Biogen hope that this prospective, large-scale commitment to supply over the next 10 years will: 

  • Enable people with haemophilia in more countries to have a better chance of reliably accessing modern treatment.
  • Make the latest long-acting technology for treating haemophilia available to people who need it.
    • Having access to long-acting treatment might be even more important for people in developing countries, where it is often a long journey to the nearest treatment centre, and where local infrastructure and transport is less developed.
  • Allow for predictability and reliability for supply.
    • Allowing treating physicians in countries where supply of treatment has traditionally been patchy or unreliable to plan effective treatment regimens for those under their care will increase the chances of people with haemophilia receiving more sustained treatment. Treaters have historically triaged patients and withheld limited supplies for emergency cases.
  • Provide in-date product the same shelf life as commercial material, ensuring product activity. 
    • We have increased production capacity to enable us to set aside a part of our regular manufactured product specifically for this donation. Our goal is to supply treatment with the same shelf life to the programme as for any commercial market.
    • Providing medicines with the same shelf-life no matter where people are in the world will reduce the chance of people being treated with out-of-date or expired products.
  • Give people with haemophilia the chance to access the latest technological treatment options.
    • Long-acting factors are the state of the art – securing that our advances are not reserved for one group of people over another underlines our commitment to do what we can to support the best outcomes for people with haemophilia, no matter where they live or their ability to pay for  treatment.

We hope that this donation will inspire other organisations to support the programme and people with haemophilia in whatever way that they can and continue the support the WFH’s drive to “Close the Gap”.